HCV-related hepatocellular carcinoma
Conditions
Interventions
Ombitasvir/paritaprevir/ritonavir therapy for HCV Patients will receive 2 tablets of Viekirax after meal once daily for 12 weeks. Each film coated tablet contains 12.5 mg of ombitasvir, 75 mg of p
Sponsors
Juntendo University Hospital
Juntendo University Nerima Hospital Japanese Red Cross Medical Center Mitsui Memorial Hospital Kyoundo Hospital Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Keio University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients at the age between 20 and 90 years old 2)Patients providing written informed consent 3)Patients who will have IFN-free therapy for HCV after curative treatment for HCC
Exclusion criteria
Exclusion criteria: 1)Patients who have a history of hypersensitivity to Omvitasvir/paritaprevir/ritonavir 2)Patients who are excluded from HCV eradication therapy because of decompensated cirrhosis and others 3)Patients who cannot receive IFN-free therapy because of concomitant medication etc. 4)Women who are or may be pregnant 5)Patients considered to be ineligible for participation in the study by the investigator or subinvestigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication ratio of HCV 24 weeks after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events and side effects Recurrence of HCC | — |
Countries
Japan
Contacts
Public ContactShuichiro Shiina
1956 Department of Gastroenterology (Department of Diagnostic Imaging and Minimally Invasive Therapy)
Outcome results
None listed